Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Viridian Therapeutics in a report released on Wednesday, August 14th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.70) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($1.00) EPS.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 89.20% and a negative net margin of 79,185.77%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million.
View Our Latest Research Report on VRDN
Viridian Therapeutics Stock Performance
NASDAQ:VRDN opened at $15.49 on Thursday. The company has a market capitalization of $988.60 million, a P/E ratio of -3.44 and a beta of 1.13. The business has a fifty day simple moving average of $14.04 and a two-hundred day simple moving average of $15.44. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. Viridian Therapeutics has a 1 year low of $10.93 and a 1 year high of $24.18.
Institutional Investors Weigh In On Viridian Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at about $13,195,000. Perceptive Advisors LLC increased its position in shares of Viridian Therapeutics by 71.1% during the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after buying an additional 719,007 shares during the period. Vanguard Group Inc. increased its position in shares of Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Viridian Therapeutics by 19.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares during the period. Finally, Knights of Columbus Asset Advisors LLC increased its position in shares of Viridian Therapeutics by 420.9% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 153,949 shares of the company’s stock valued at $3,353,000 after buying an additional 124,396 shares during the period.
About Viridian Therapeutics
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
- Five stocks we like better than Viridian Therapeutics
- What is the NASDAQ Stock Exchange?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Investing In Preferred Stock vs. Common Stock
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.